Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07465679) titled 'A Real-world Study of Clinical Treatment Guidelines for Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan' on March 6.
Study Type: Observational
Primary Sponsor: Novartis Pharmaceuticals
Condition:
Heart Failure With Reduced Ejection Fraction
Recruitment Status: Not recruiting
Date of First Enrollment: January 28, 2026
Target Sample Size: 500
Countries of Recruitment:
Romania
To know more, visit https://clinicaltrials.gov/study/NCT07465679
Published by HT Digital Content Services with permission from Health Daily Digest....